International Journal of Cancer Care and Delivery
Real-World Comparative Effectiveness and Safety of BTK Inhibitors Versus Chemoimmunotherapy for Frontline Waldenstrom Macroglobulinemia
By Priyadeep Kaur, Hamza Hassan and Shaniza Haniff.
Abstract
BackgroundNo randomized trial has compared Bruton tyrosine kinase inhibitor (BTKi)-based therapy with chemoimmunotherapy (CIT) in frontline Waldenström macroglobulinemia (WM); the RAINBOW trial (NCT04061512) is ongoing.Real-world data are therefore the only current evidence, particularly for older adults, who make up most patients and are underrepresented in trials.
Keywords
- Chronic Lymphocytic Leukemia Research
- Open access
Source
Published in International Journal of Cancer Care and Delivery. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
At a glance
- Type